{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:38:24Z","timestamp":1793147904067,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K16359"],"award-info":[{"award-number":["22K16359"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nagahama City"},{"name":"Toyooka City"},{"DOI":"10.13039\/100010740","name":"Asahi Kasei Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010740","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020830","name":"AYUMI Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020830","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jansen K.K."},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015990","name":"Sanofi K.K.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015990","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Taisho Pharmaceutical Holdings"},{"DOI":"10.13039\/501100010486","name":"Teijin Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010486","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UCB Japan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-025-03541-8","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T04:10:12Z","timestamp":1742962212000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Predicting rheumatoid arthritis progression from seronegative undifferentiated arthritis using machine learning: a deep learning model trained on the KURAMA cohort and externally validated with the ANSWER cohort"],"prefix":"10.1186","volume":"27","author":[{"given":"Takayuki","family":"Fujii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohiko","family":"Kohjitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosaku","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Etani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Okita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naofumi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Amuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yo","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaichi","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Morinobu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"3541_CR1","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"3541_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/BOR.0000000000001007","volume":"36","author":"E Myasoedova","year":"2024","unstructured":"Myasoedova E, Matteson EL. Updates on interstitial lung disease and other selected extra-articular manifestations of rheumatoid arthritis. Curr Opin Rheumatol. 2024;36(3):203\u20138.","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"3541_CR3","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1136\/annrheumdis-2013-204867","volume":"74","author":"J Sorensen","year":"2015","unstructured":"Sorensen J, Hetland ML. All departments of rheumatology in D. Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Ann Rheum Dis. 2015;74(3):e12.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"3541_CR4","doi-asserted-by":"publisher","first-page":"e000057","DOI":"10.1136\/rmdopen-2015-000057","volume":"1","author":"S Monti","year":"2015","unstructured":"Monti S, Montecucco C, Bugatti S, Caporali R. Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD Open. 2015;1(Suppl 1):e000057.","journal-title":"RMD Open"},{"issue":"9","key":"3541_CR5","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American college of rheumatology\/european league against rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569\u201381.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"3541_CR6","doi-asserted-by":"publisher","first-page":"e000573","DOI":"10.1136\/rmdopen-2017-000573","volume":"3","author":"ES Norli","year":"2017","unstructured":"Norli ES, Brinkmann GH, Kvien TK, et al. Diagnostic spectrum and 2-year outcome in a cohort of patients with very early arthritis. RMD Open. 2017;3(2):e000573.","journal-title":"RMD Open"},{"issue":"7","key":"3541_CR7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nrrheum.2011.78","volume":"7","author":"JM Hazes","year":"2011","unstructured":"Hazes JM, Luime JJ. The epidemiology of early inflammatory arthritis. Nat Rev Rheumatol. 2011;7(7):381\u201390.","journal-title":"Nat Rev Rheumatol"},{"key":"3541_CR8","doi-asserted-by":"publisher","first-page":"668898","DOI":"10.3389\/fmed.2021.668898","volume":"8","author":"M Novella-Navarro","year":"2021","unstructured":"Novella-Navarro M, Plasencia-Rodriguez C, Nuno L, Balsa A. Risk factors for developing rheumatoid arthritis in patients with undifferentiated arthritis and inflammatory arthralgia. Front Med (Lausanne). 2021;8:668898.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"3541_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrrheum.2017.185","volume":"14","author":"HW van Steenbergen","year":"2018","unstructured":"van Steenbergen HW, da Silva JAP, Huizinga TWJ, van der Helm-van Mil AHM. Preventing progression from arthralgia to arthritis: targeting the right patients. Nat Rev Rheumatol. 2018;14(1):32\u201341.","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"3541_CR10","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1136\/annrheumdis-2012-203165","volume":"72","author":"KV Wevers-de Boer","year":"2013","unstructured":"Wevers-de Boer KV, Heimans L, Huizinga TW, Allaart CF. Drug therapy in undifferentiated arthritis: a systematic literature review. Ann Rheum Dis. 2013;72(9):1436\u201344.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"3541_CR11","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1093\/rheumatology\/keab880","volume":"61","author":"M Verstappen","year":"2022","unstructured":"Verstappen M, Matthijssen XME, van der Helm-van Mil AHM. Undifferentiated arthritis: a changing population who did not benefit from enhanced disease-modifying anti-rheumatic drug strategies-results from a 25 year longitudinal inception cohort. Rheumatology (Oxford). 2022;61(8):3212\u201322.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"3541_CR12","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/art.22380","volume":"56","author":"AH van der Helm","year":"2007","unstructured":"van der Helm AH, le Cessie S, van Dongen H, Breedveld FC, Toes RE, Huizinga TW. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum. 2007;56(2):433\u201340.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"3541_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4103\/amhsr.amhsr_339_15","volume":"6","author":"K Ghosh","year":"2016","unstructured":"Ghosh K, Chatterjee A, Ghosh S, et al. Validation of Leiden score in predicting progression of rheumatoid arthritis in undifferentiated arthritis in Indian population. Ann Med Health Sci Res. 2016;6(4):205\u201310.","journal-title":"Ann Med Health Sci Res"},{"issue":"13","key":"3541_CR14","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: A review. JAMA. 2018;320(13):1360\u201372.","journal-title":"JAMA"},{"issue":"7","key":"3541_CR15","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1093\/rheumatology\/keq442","volume":"50","author":"Y Kaneko","year":"2011","unstructured":"Kaneko Y, Kuwana M, Kameda H, Takeuchi T. Sensitivity and specificity of 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford). 2011;50(7):1268\u201374.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"3541_CR16","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1136\/annrheumdis-2012-201909","volume":"72","author":"I Biliavska","year":"2013","unstructured":"Biliavska I, Stamm TA, Martinez-Avila J, et al. Application of the 2010 ACR\/EULAR classification criteria in patients with very early inflammatory arthritis: analysis of sensitivity, specificity and predictive values in the SAVE study cohort. Ann Rheum Dis. 2013;72(8):1335\u201341.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"3541_CR17","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1136\/ard.2008.105759","volume":"69","author":"WH Bos","year":"2010","unstructured":"Bos WH, Wolbink GJ, Boers M, et al. Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis. 2010;69(3):490\u20134.","journal-title":"Ann Rheum Dis"},{"key":"3541_CR18","doi-asserted-by":"publisher","first-page":"e5244","DOI":"10.1136\/bmj.e5244","volume":"345","author":"SF Nielsen","year":"2012","unstructured":"Nielsen SF, Bojesen SE, Schnohr P, Nordestgaard BG. Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study. BMJ. 2012;345:e5244.","journal-title":"BMJ"},{"issue":"10429","key":"3541_CR19","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S0140-6736(23)02650-8","volume":"403","author":"J Rech","year":"2024","unstructured":"Rech J, Tascilar K, Hagen M, et al. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial. Lancet. 2024;403(10429):850\u20139.","journal-title":"Lancet"},{"issue":"1","key":"3541_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/ard.2005.038471","volume":"65","author":"J van Aken","year":"2006","unstructured":"van Aken J, van Dongen H, le Cessie S, Allaart CF, Breedveld FC, Huizinga TW. Comparison of long term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study. Ann Rheum Dis. 2006;65(1):20\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"3541_CR21","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1002\/art.41885","volume":"73","author":"C de la Calle-Fabregat","year":"2021","unstructured":"de la Calle-Fabregat C, Niemantsverdriet E, Canete JD, et al. Prediction of the progression of undifferentiated arthritis to rheumatoid arthritis using DNA methylation profiling. Arthritis Rheumatol. 2021;73(12):2229\u201339.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"3541_CR22","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3899\/jrheum.160693","volume":"44","author":"GH Brinkmann","year":"2017","unstructured":"Brinkmann GH, Norli ES, Kvien TK, et al. Disease characteristics and rheumatoid arthritis development in patients with early undifferentiated arthritis: A 2-year followup study. J Rheumatol. 2017;44(2):154\u201361.","journal-title":"J Rheumatol"},{"issue":"4","key":"3541_CR23","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2174\/1389202922666210705124359","volume":"22","author":"H Habehh","year":"2021","unstructured":"Habehh H, Gohel S. Machine learning in healthcare. Curr Genomics. 2021;22(4):291\u2013300.","journal-title":"Curr Genomics"},{"issue":"1","key":"3541_CR24","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1038\/s41467-020-17419-7","volume":"11","author":"JG Richens","year":"2020","unstructured":"Richens JG, Lee CM, Johri S. Improving the accuracy of medical diagnosis with causal machine learning. Nat Commun. 2020;11(1):3923.","journal-title":"Nat Commun"},{"issue":"1","key":"3541_CR25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41591-018-0316-z","volume":"25","author":"A Esteva","year":"2019","unstructured":"Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare. Nat Med. 2019;25(1):24\u20139.","journal-title":"Nat Med"},{"key":"3541_CR26","doi-asserted-by":"crossref","unstructured":"Baker JF. Diagnosis and differential diagnosis of rheumatoid arthritis. In: UpToDate, ed. UpToDate: Wolters Kluwer. (Accessed on July 7, 2024.).","DOI":"10.1097\/01.COT.0001017048.09139.77"},{"issue":"10","key":"3541_CR27","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1136\/annrheumdis-2012-201426","volume":"71","author":"AH van der Helm","year":"2012","unstructured":"van der Helm AH, Huizinga TW. The 2010 ACR\/EULAR criteria for rheumatoid arthritis: do they affect the classification or diagnosis of rheumatoid arthritis? Ann Rheum Dis. 2012;71(10):1596\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3541_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13075-023-03251-z","volume":"26","author":"T Fujii","year":"2024","unstructured":"Fujii T, Murata K, Onizawa H, et al. Management and treatment outcomes of rheumatoid arthritis in the era of biologic and targeted synthetic therapies: evaluation of 10-year data from the KURAMA cohort. Arthritis Res Ther. 2024;26(1):16.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"3541_CR29","doi-asserted-by":"publisher","first-page":"e15168","DOI":"10.1111\/1756-185X.15168","volume":"27","author":"T Fujii","year":"2024","unstructured":"Fujii T, Murata K, Onizawa H, et al. The influence of medial cuneiform inclination on postoperative hallux valgus recurrence in rheumatoid arthritis patients: insights from the KURAMA cohort study. Int J Rheum Dis. 2024;27(5):e15168.","journal-title":"Int J Rheum Dis"},{"key":"3541_CR30","doi-asserted-by":"publisher","first-page":"901437","DOI":"10.3389\/fimmu.2022.901437","volume":"13","author":"T Iwasaki","year":"2022","unstructured":"Iwasaki T, Watanabe R, Ito H, et al. Dynamics of type I and type II interferon signature determines responsiveness to Anti-TNF therapy in rheumatoid arthritis. Front Immunol. 2022;13:901437.","journal-title":"Front Immunol"},{"issue":"4","key":"3541_CR31","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/mr\/roab043","volume":"32","author":"K Murata","year":"2022","unstructured":"Murata K, Uozumi R, Hashimoto M, et al. The real-world effectiveness of anti-RANKL antibody denosumab on the clinical fracture prevention in patients with rheumatoid arthritis: the ANSWER cohort study. Mod Rheumatol. 2022;32(4):834\u20138.","journal-title":"Mod Rheumatol"},{"key":"3541_CR32","unstructured":"Hayashi S, Tachibana S, Maeda T et al. Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. Rheumatology (Oxford) 2023."},{"key":"3541_CR33","doi-asserted-by":"crossref","unstructured":"Ebina K, Etani Y, Maeda Y et al. Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. RMD Open 2023; 9(3).","DOI":"10.1136\/rmdopen-2023-003160"},{"issue":"1","key":"3541_CR34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s10238-024-01360-w","volume":"24","author":"Y Nakayama","year":"2024","unstructured":"Nakayama Y, Onishi A, Yamamoto W, et al. Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study. Clin Exp Med. 2024;24(1):97.","journal-title":"Clin Exp Med"},{"issue":"4","key":"3541_CR35","doi-asserted-by":"publisher","first-page":"R796","DOI":"10.1186\/ar1740","volume":"7","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005;7(4):R796\u2013806.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"3541_CR36","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/art.1780230202","volume":"23","author":"JF Fries","year":"1980","unstructured":"Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23(2):137\u201345.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"3541_CR37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12859-023-05156-9","volume":"24","author":"D Rajput","year":"2023","unstructured":"Rajput D, Wang WJ, Chen CC. Evaluation of a decided sample size in machine learning applications. BMC Bioinformatics. 2023;24(1):48.","journal-title":"BMC Bioinformatics"},{"issue":"1","key":"3541_CR38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.7326\/M14-0697","volume":"162","author":"GS Collins","year":"2015","unstructured":"Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. 2015;162(1):55\u201363.","journal-title":"Ann Intern Med"},{"issue":"10","key":"3541_CR39","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/art.1780311004","volume":"31","author":"A del Puente","year":"1988","unstructured":"del Puente A, Knowler WC, Pettitt DJ, Bennett PH. The incidence of rheumatoid arthritis is predicted by rheumatoid factor titer in a longitudinal population study. Arthritis Rheum. 1988;31(10):1239\u201344.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"3541_CR40","doi-asserted-by":"publisher","first-page":"R16","DOI":"10.1186\/ar4148","volume":"15","author":"N Bizzaro","year":"2013","unstructured":"Bizzaro N, Bartoloni E, Morozzi G, et al. Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study. Arthritis Res Ther. 2013;15(1):R16.","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"3541_CR41","doi-asserted-by":"publisher","first-page":"e15358","DOI":"10.1111\/1756-185X.15358","volume":"27","author":"R Saito","year":"2024","unstructured":"Saito R, Fujii T, Murata K, et al. Prediction models incorporating second metacarpal cortical index for osteoporosis in rheumatoid arthritis: externally validated machine learning models developed using data from the KURAMA cohort. Int J Rheum Dis. 2024;27(10):e15358.","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"3541_CR42","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/bjaceaccp\/mkn041","volume":"8","author":"AG Lalkhen","year":"2008","unstructured":"Lalkhen AG, McCluskey A. Clinical tests: sensitivity and specificity. Continuing Educ Anaesth Crit Care Pain. 2008;8(6):221\u20133.","journal-title":"Continuing Educ Anaesth Crit Care Pain"},{"issue":"4","key":"3541_CR43","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1213\/ANE.0000000000003698","volume":"127","author":"TR Vetter","year":"2018","unstructured":"Vetter TR, Schober P, Mascha EJ. Diagnostic testing and Decision-Making: beauty is not just in the eye of the beholder. Anesth Analg. 2018;127(4):1085\u201391.","journal-title":"Anesth Analg"},{"issue":"10","key":"3541_CR44","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41551-018-0304-0","volume":"2","author":"SM Lundberg","year":"2018","unstructured":"Lundberg SM, Nair B, Vavilala MS, et al. Explainable machine-learning predictions for the prevention of hypoxaemia during surgery. Nat Biomed Eng. 2018;2(10):749\u201360.","journal-title":"Nat Biomed Eng"},{"issue":"4","key":"3541_CR45","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1136\/annrheumdis-2019-216694","volume":"79","author":"E Myasoedova","year":"2020","unstructured":"Myasoedova E, Davis J, Matteson EL, Crowson CS. Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985\u20132014. Ann Rheum Dis. 2020;79(4):440\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3541_CR46","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00296-024-05591-8","volume":"44","author":"M Krajewska-Wlodarczyk","year":"2024","unstructured":"Krajewska-Wlodarczyk M, Szelag M, Batko B, et al. Rheumatoid arthritis epidemiology: a nationwide study in Poland. Rheumatol Int. 2024;44(6):1155\u201363.","journal-title":"Rheumatol Int"},{"issue":"1","key":"3541_CR47","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41746-023-00875-y","volume":"6","author":"D Huang","year":"2023","unstructured":"Huang D, Cogill S, Hsia RY, Yang S, Kim D. Development and external validation of a pretrained deep learning model for the prediction of non-accidental trauma. NPJ Digit Med. 2023;6(1):131.","journal-title":"NPJ Digit Med"},{"issue":"7","key":"3541_CR48","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","volume":"80","author":"B Combe","year":"2021","unstructured":"Combe B, Kivitz A, Tanaka Y, et al. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis. 2021;80(7):848\u201358.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"3541_CR49","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652\u201362.","journal-title":"N Engl J Med"},{"key":"3541_CR50","doi-asserted-by":"crossref","unstructured":"Perniola S, Chimenti MS, Spinelli FR et al. Rheumatoid Arthritis from Easy to Complex Disease: From the 2022 GISEA International Symposium. J Clin Med 2023; 12(8).","DOI":"10.3390\/jcm12082781"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03541-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03541-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03541-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T05:59:17Z","timestamp":1743314357000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-025-03541-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3541"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03541-8","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"3 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T.F. has received speaker fees from AbbVie GK, Astellas Pharma Inc, Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Co., Taisho Pharmaceutical Co., Ltd., and Janssen Pharmaceutical K.K. K.Murata received research grants and\/or speaker fees from Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Pfizer Inc., Bristol-Myers Squibb, Mitsubishi Tanabe Pharma Corporation, UCB Japan Co., Ltd., Daiichi Sankyo Co., Ltd., and Astellas Pharma Inc. A.O. received research grants and speaker fees from Pfizer Inc., Bristol Myers Squibb, Advantest, Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K. K., Ono Pharmaceutical Co., UCB Japan Co., Mitsubishi Tanabe Pharma Co., Eisai Co. Ltd., AbbVie Inc., Takeda Pharmaceutical Co. Ltd., and Daiichi Sankyo Co. Ltd. K.Murakami received speaking and\/or consulting fees from AbbVie GK, Eisai Co., Ltd., Pfizer Inc., Chugai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corp., Bristol-Myers Squibb, Daiichi Sankyo Co., Ltd., Janssen Pharmaceutical K.K., and Asahi Kasei Pharma Corp. M.T. has received research grants and\/or speaker fees from AbbVie GK, Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Kyowa Kirin Co., Ltd., Pfizer Inc., Taisho Pharmaceutical Co., Ltd., Tanabe Mitsubishi Pharma Corp., Teijin Pharma, Ltd., UCB Japan Co., Ltd. K.N. has received speaker fees from Pfizer Inc., Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K. K., Ono Pharmaceutical Co., UCB Japan Co., Mitsubishi Tanabe Pharma Co., Eisai Co. Ltd., AbbVie Inc., Janssen Pharmaceutical K.K., Taisho Pharmaceutical Co., Ltd, and Viatris Inc. Y.E. received research grants and\/or speaker fees from Asahi Kasei, Eisai, Eli Lilly, Mitsubishi Tanabe, Ono Pharmaceuticals, and Taisho. Y.E. is affiliated with the Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, supported by Asahi Kasei. Y.O. has received lecture fees from Chugai, Pfizer and Ono. H. A. has received speaker fees from Asahi Kasei Pharma, Chugai Pharmaceutical Co., Ltd, Eisai Co., Ltd, Taisho Pharmaceutical Co., and Mitsubishi Tanabe Pharma. T.O. has received research grants from Abbvie, Asahi Kasei, Chugai, Eisai, and Tanabe Mitsubishi, and speaker fees from Abbvie, Asahi Kasei, Chugai, Eisai, Eli Lilly, Janssen, Novartis Pharma and Tanabe Mitsubishi. K. Y.U. has received speaker fees from AbbVie, Asahi Kasei Pharma, Astellas, Bristol Meyers Squibb, Chugai, Eisai, Eli Lilly, Gilead Sciences, and Taiho Pharmaceutical. R.H. received speaker fees from AbbVie, Eli Lilly, Eisai, and Asahi Kasei. M.H. received research grants and\/or speaker fees from AbbVie, Asahi Kasei, Astellas, Brystol Meyers, Chugai, EA Pharma, Eisai, Daiichi Sankyo, Eli Lilly, Novartis Pharma, Taisho Toyama, and Tanabe Mitsubishi. A.M. received honorarium and research grants from AbbVie G.K., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Eisai Co. Ltd., Pfizer Inc., Bristol-Myers Squibb., Mitsubishi Tanabe Pharma Co., Astellas Pharma Inc., Asahi Kasei Pharma Corp., and Gilead Sciences Japan. S.M. received research grants and\/or speaker fees from Takeda, Eisai, Asahi-Kasei, Astellas, Pfizer, Taisho, Mitsubishi-Tanabe, and Chugai. Other authors have no conflicts of interest to disclose concerning this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The institutional review board at all hospitals participating in the KURAMA and the ANSWER cohorts approved this study. Written informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"65"}}